Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/352841
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Loucera, Carlos | es_ES |
dc.contributor.author | Carmona, Rosario | es_ES |
dc.contributor.author | Esteban-Medina, Marina | es_ES |
dc.contributor.author | Bostelmann, Gerrit | es_ES |
dc.contributor.author | Muñoyerro-Muñiz, Dolores | es_ES |
dc.contributor.author | Villegas, Román | es_ES |
dc.contributor.author | Peña-Chilet, María | es_ES |
dc.contributor.author | Dopazo, Joaquín | es_ES |
dc.date.accessioned | 2024-04-04T09:44:30Z | - |
dc.date.available | 2024-04-04T09:44:30Z | - |
dc.date.issued | 2023-10-06 | - |
dc.identifier.citation | Loucera, Carlos; Carmona, Rosario; Esteban-Medina, Marina; Bostelmann, Gerrit; Muñoyerro-Muñiz, Dolores; Villegas, Román; Peña-Chilet, María; Dopazo, Joaquín; 2023; "Supplementary Material: Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments [Dataset]"; BMC; https://doi.org/10.1186/s12985-023-02195-9 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10261/352841 | - |
dc.description | Supplementary Tables: Table S1. Data imported from BPS for each patient: code and definition of the variable.-- Table S2: Log Hazard ratios obtained for the drugs tested, along with standard deviations (SDs), upper and lower coefficient intervals (CI), nominal and FDR-adjusted p-values. Also, Lymphocyte proliferation values (see Methods) along with standard deviations (SDs), upper and lower coefficient intervals (CI), nominal and FDR-adjusted p-values. The two last columns indicate the drugs used in the machine learning drug repurposing prediction study and the proteins targeted by the drug. Targets marked with an * were those analyzed in the machine learning drug repurposing. | es_ES |
dc.description.abstract | [Purpose] Despite the extensive vaccination campaigns in many countries, COVID-19 is still a major worldwide health problem because of its associated morbidity and mortality. Therefore, finding efficient treatments as fast as possible is a pressing need. Drug repurposing constitutes a convenient alternative when the need for new drugs in an unexpected medical scenario is urgent, as is the case with COVID-19. | es_ES |
dc.description.abstract | [Methods] Using data from a central registry of electronic health records (the Andalusian Population Health Database), the effect of prior consumption of drugs for other indications previous to the hospitalization with respect to patient outcomes, including survival and lymphocyte progression, was studied on a retrospective cohort of 15,968 individuals, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. | es_ES |
dc.description.abstract | [Results] Covariate-adjusted hazard ratios and analysis of lymphocyte progression curves support a significant association between consumption of 21 different drugs and better patient survival. Contrarily, one drug, furosemide, displayed a significant increase in patient mortality. | es_ES |
dc.description.abstract | [Conclusions] In this study we have taken advantage of the availability of a regional clinical database to study the effect of drugs, which patients were taking for other indications, on their survival. The large size of the database allowed us to control covariates effectively. | es_ES |
dc.description.sponsorship | This research was funded by Spanish Ministry of Science and Innovation (grant PID2020-117979RB-I00), the Instituto de Salud Carlos III (ISCIII), co-funded with European Regional Development Funds (ERDF) (grant IMP/00019), and has also been funded by Consejería de Salud y Consumo, Junta de Andalucía (grants COVID-0012-2020, PS-2020-342 and IE19_259 FPS) and the postdoctoral contract of Carlos Loucera (PAIDI2020- DOC_00350) co-funded by the European Social Fund (FSE) 2014–2020. | es_ES |
dc.format | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BioMed Central | es_ES |
dc.publisher | Springer Nature | es_ES |
dc.relation | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-117979RB-I00/ES/MEDICINA INTERCEPTIVA, DESCUBRIMIENTO DE DIANAS Y REUTILIZACION DE FARMACOS MEDIANTE MODELOS MECANISTICOS Y APRENDIZAJE SUPERVISADO/ | es_ES |
dc.relation.isreferencedby | Loucera, Carlos; Carmona, Rosario; Esteban-Medina, Marina; Bostelmann, Gerrit; Muñoyerro-Muñiz, Dolores; Villegas, Román; Peña-Chilet, María; Dopazo, Joaquín. Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments. https://doi.org/10.1186/s12985-023-02195-9. http://hdl.handle.net/10261/352838 | es_ES |
dc.rights | openAccess | es_ES |
dc.subject | Drug repurposing | es_ES |
dc.subject | COVID-19 | es_ES |
dc.subject | Real world data | es_ES |
dc.subject | Real world evidence | es_ES |
dc.subject | Retrospective cohort | es_ES |
dc.title | Supplementary Material: Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments | es_ES |
dc.type | dataset | es_ES |
dc.identifier.doi | 10.1186/s12985-023-02195-9 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | https://doi.org/10.1186/s12985-023-02195-9 | es_ES |
dc.identifier.e-issn | 1743-422X | - |
dc.rights.license | https://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | es_ES |
dc.contributor.funder | Agencia Estatal de Investigación (España) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Junta de Andalucía | es_ES |
dc.contributor.funder | European Commission | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/501100011033 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100011011 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_ddb1 | es_ES |
item.cerifentitytype | Products | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_ddb1 | - |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
item.openairetype | dataset | - |
Aparece en las colecciones: | (IBIS) Conjuntos de datos (PTI Salud Global) Colección Especial COVID-19 |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
12985_2023_2195_MOESM1_ESM.pdf | 468,15 kB | Adobe PDF | Visualizar/Abrir | |
12985_2023_2195_MOESM1_ESM_readme.txt | 4,5 kB | Text | Visualizar/Abrir |
CORE Recommender
Page view(s)
12
checked on 16-may-2024
Download(s)
2
checked on 16-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons